Avidity Partners Management’s Verona Pharma VRNA Stock Holding History

Avidity Partners Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-33,800	Closed	-$3.2M	–	67
2025 Q2	$3.2M	Buy	+33,800	New	+$2.5M	0.64%	40
2024 Q1	–	Sell	-780,900	Closed	-$15.5M	–	104
2023 Q4	$15.5M	Sell	780,900 -49,400	-6%	-$729K	0.57%	52
2023 Q3	$13.5M	Sell	830,300 -124,200	-13%	-$2.39M	0.55%	59
2023 Q2	$20.2M	Buy	954,500 +75,700	+9%	+$1.61M	0.7%	52
2023 Q1	$17.6M	Buy	+878,800	New	+$19M	0.59%	54

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avidity Partners Management's VRNA Position: Q3 2025 in Review

Avidity Partners Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 33,800 shares — an estimated $3.2M sold.

Avidity Partners Management first reported a position in VRNA in Q1 2023 and held it in 5 quarters. The position peaked at $20.2M in Q2 2023. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Avidity Partners Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Avidity Partners Management sold 33,800 Verona Pharma shares in Q3 2025, an estimated $3.2M.
Avidity Partners Management first reported a position in Verona Pharma in Q1 2023 and held it in 5 quarters.
Avidity Partners Management's Verona Pharma position peaked at $20.2M in Q2 2023.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.